A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is investigating a treatment called vutrisiran for people with a heart condition known as transthyretin amyloidosis (ATTR cardiomyopathy). This condition causes abnormal protein deposits to build up in the heart, making it harder for the heart to work properly. The main goal of this research is to gather more information about how safe and helpful vutrisiran is for patients who have previously been involved in other studies with vutrisiran or a similar medication called patisiran. Researchers will be looking at how well the medicine works and any side effects people might experience during the study.
במבט חטוף
על מה המחקר הזה?
This research study is about a condition called transthyretin amyloidosis (ATTR) with cardiomyopathy. Cardiomyopathy means that the heart muscle has become diseased, making it harder for the heart to pump blood effectively. In ATTR, a protein called transthyretin misfolds and builds up into deposits, known as amyloid, in various organs, including the heart. These amyloid deposits stop the heart from working as it should.
The study is focusing on a specific medicine called vutrisiran. This treatment is being looked at to see how well it works and if it's safe for people who have this particular heart condition. Researchers want to understand if vutrisiran can help manage the condition and improve the lives of patients.
Specifically, this study is for individuals who have already been taking vutrisiran in a previous study or who have switched to vutrisiran from another similar medication called patisiran. By continuing to monitor these patients, the researchers hope to gain more long-term information about vutrisiran's effects, gather further safety data, and assess its overall effectiveness in a real-world setting.
נקודות עיקריות
- This study focuses on a heart condition called ATTR cardiomyopathy.
- It investigates the safety and effectiveness of a medicine called vutrisiran.
- This is for patients who have already used vutrisiran or similar treatments in prior studies.
- It's a Phase 3 study, a later stage of drug development.
- The aim is to gather more long-term information on the treatment.
מי עשוי להיות זכאי?
To be considered for this study, you must have previously taken part in one of the parent studies for patisiran (ALN-TTR02-011 or ALN-TTR02-014) or completed an extended treatment period in the vutrisiran parent study (ALN-TTRSC02-003).
There are also some reasons why you might not be able to join. For example, if you stopped taking the study medication permanently in those earlier studies, you wouldn't be able to participate. You also can't be involved in another research study for a new drug or device at the same time as this one.
Finally, if you have other health conditions that the study doctors believe would make it difficult for you to follow the study rules or for them to understand your results, you might not be eligible.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- Have I previously participated in a study for patisiran (ALN-TTR02-011 or ALN-TTR02-014)?
- Have I completed the 24-month treatment period in the vutrisiran parent study (ALN-TTRSC02-003)?
- Have I permanently stopped taking the study drug in any of those previous studies?
- Am I currently or planning to be in another research study for a new drug or device?
מה כרוך בהשתתפות?
The detailed involvement in this study would be explained fully by the study team. As this study is for patients who have already been taking vutrisiran or patisiran, it is likely to involve continued monitoring of your health and the effects of vutrisiran. This would typically include regular visits to the study clinic, where you might have physical examinations, blood tests, and other assessments to check your heart function and overall health. You would continue to receive vutrisiran as part of the study. The total duration of your participation would be clearly outlined by the study team.
סיכונים ותועלות פוטנציאליים
מיקומים (87)
- Clinical Trial Siteמיקוד מאומתפניקס, ארצות הברית
- Clinical Trial Siteמיקוד מאומתבוורלי הילס, ארצות הברית
- Clinical Trial Siteמיקוד מאומתלה הויה, ארצות הברית
- Clinical Trial Siteמיקוד מאומתסטנפורד, ארצות הברית
- Clinical Trial Siteמיקוד מאומתוושינגטון די.סי., ארצות הברית
- Clinical Trial Siteמיקוד מאומתשיקגו, ארצות הברית
- Clinical Trial Siteמיקוד מאומתGlenview, United States
- Clinical Trial Siteמיקוד מאומתאינדיאנפוליס, ארצות הברית
- Clinical Trial Siteמיקוד מאומתקנזס סיטי, ארצות הברית
- Clinical Trial Siteמיקוד מאומתבולטימור, ארצות הברית
- Clinical Trial Siteמיקוד מאומתבוסטון, ארצות הברית
- Clinical Trial Siteמיקוד מאומתבוסטון, ארצות הברית
שאלות נפוצות
What is ATTR cardiomyopathy?
ATTR cardiomyopathy is a heart condition where special proteins called transthyretin misfold and build up in your heart, making it harder for your heart to work properly.
What is vutrisiran?
Vutrisiran is a medicine being studied as a treatment for ATTR cardiomyopathy. This study aims to understand its safety and effectiveness.
Can anyone with ATTR cardiomyopathy join this study?
No, this specific study is for people who have already taken part in previous studies involving vutrisiran or a similar medication called patisiran.
מה המשמעות של 'שלב 3' עבור מחקר?
Phase 3 means the study is in a later stage of research, where the medicine has already shown some promise. It involves a larger number of patients to confirm how well it works and its safety before it can be approved for general use.
האם אצטרך לשלם כדי להשתתף במחקר?
Generally, clinical trials cover the costs of study-related medication and procedures. This would be fully explained to you before you agree to participate.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.